Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA – Get Rating) – Stock analysts at Wedbush issued their FY2026 EPS estimates for shares of Kiniksa Pharmaceuticals in a report issued on Wednesday, August 3rd. Wedbush analyst D. Nierengarten expects that the company will post earnings of ($0.31) per share for the year. The consensus estimate for Kiniksa Pharmaceuticals’ current full-year earnings is ($1.61) per share.
Kiniksa Pharmaceuticals Stock Performance
Shares of KNSA opened at $13.41 on Friday. The firm has a market cap of $928.99 million, a price-to-earnings ratio of -8.28 and a beta of -0.12. Kiniksa Pharmaceuticals has a fifty-two week low of $7.36 and a fifty-two week high of $15.24. The firm has a 50 day moving average price of $9.96 and a 200-day moving average price of $10.03.
Institutional Investors Weigh In On Kiniksa Pharmaceuticals
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Pictet Asset Management SA raised its holdings in Kiniksa Pharmaceuticals by 6.4% during the 4th quarter. Pictet Asset Management SA now owns 3,548,649 shares of the company’s stock valued at $41,768,000 after buying an additional 213,744 shares during the last quarter. BlackRock Inc. raised its holdings in Kiniksa Pharmaceuticals by 0.3% during the 1st quarter. BlackRock Inc. now owns 3,494,325 shares of the company’s stock valued at $34,734,000 after buying an additional 10,473 shares during the last quarter. Vanguard Group Inc. raised its holdings in Kiniksa Pharmaceuticals by 4.0% during the 1st quarter. Vanguard Group Inc. now owns 3,006,650 shares of the company’s stock valued at $29,886,000 after buying an additional 115,942 shares during the last quarter. Great Point Partners LLC raised its holdings in Kiniksa Pharmaceuticals by 108.3% during the 1st quarter. Great Point Partners LLC now owns 1,118,067 shares of the company’s stock valued at $11,114,000 after buying an additional 581,329 shares during the last quarter. Finally, Goldman Sachs Group Inc. raised its holdings in Kiniksa Pharmaceuticals by 61.7% during the 1st quarter. Goldman Sachs Group Inc. now owns 936,604 shares of the company’s stock valued at $9,310,000 after buying an additional 357,387 shares during the last quarter. 42.57% of the stock is currently owned by institutional investors.
Kiniksa Pharmaceuticals Company Profile
Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, which is in Phase 2a clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.
- Get a free copy of the StockNews.com research report on Kiniksa Pharmaceuticals (KNSA)
- MarketBeat: Week in Review 8/1 – 8/5
- How to Use High Beta Stocks to Maximize Your Investing Profits
- Cronos Group Inc’s Revenues Are Up, Is It Time to Buy?
- Why Apple Could Be At All-Time Highs By Year End
- Beyond Meat Is Not Beyond Hope, And It’s Cheap
Receive News & Ratings for Kiniksa Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kiniksa Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.